In the present study, we discovered that (a) lnc‐ITSN1‐2 was highly expressed in AIS patients compared to the controls, and it displayed a good predictive value for AIS risk; (b) lnc‐ITSN1‐2 high expression was associated with worse disease severity and increased inflammation in AIS patients; and (c) lnc‐ITSN1‐2 high expression was associated with poor RFS in AIS patients. Here, ITSN1 is linked to androgen insensitivity syndrome.